Lee Michael Xiang, Saif Muhammad Wasif
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.
JOP. 2009 Mar 9;10(2):104-8.
Cancer of the pancreas is the fourth leading cause of cancer mortality in the United States. The annual death rate from the disease almost equals the annual incidence due to the aggressive nature of the cancer as well as to the lack of effective means of screening for it during its early curable stage. Molecular markers and imaging have not proven to be accurate modalities for screening for pancreatic cancer. The diagnosis and management of pancreatic cancer continues to be an overwhelming challenge. The authors discuss the current status of screening for pancreatic cancer and summarize relevant studies presented in the 2009 GI Cancers Symposium: utility of endoscopic ultrasound in screening high risk patients (Abstract #112), diagnostic performance of a highly specific antibody for MUC1 (Abstract #113), use of metabonomics for the early detection of pancreatic adenocarcinoma (Abstract #126), and a report on the potential impact of delay in diagnosis and treatment on pancreatic cancer outcomes at a tertiary care center (Abstract #137).
胰腺癌是美国癌症死亡的第四大主要原因。由于这种癌症具有侵袭性，且在其早期可治愈阶段缺乏有效的筛查手段，该疾病的年死亡率几乎等同于年发病率。分子标志物和影像学检查尚未被证明是筛查胰腺癌的准确方法。胰腺癌的诊断和治疗仍然是一项极具挑战性的任务。作者们讨论了胰腺癌筛查的现状，并总结了在2009年胃肠道癌症研讨会上发表的相关研究：内镜超声在筛查高危患者中的应用（摘要#112）、一种针对MUC1的高特异性抗体的诊断性能（摘要#113）、代谢组学用于早期检测胰腺腺癌（摘要#126），以及一份关于三级医疗中心诊断和治疗延迟对胰腺癌预后潜在影响的报告（摘要#137）。
